{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:45:29Z","timestamp":1786149929181,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ygyno.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:19:51Z","timestamp":1784067591000},"page":"171-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium"],"prefix":"10.1016","volume":"211","author":[{"given":"Emma L.","family":"Barber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Moroney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario R.","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Dobinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Shramuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masha","family":"Kocherginsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2026.07.001_bb0005","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0010","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0020","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic oncology group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0025","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC clinical trials group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2012.12.022","article-title":"Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic oncology group study","volume":"129","author":"Alvarez","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0035","article-title":"Hormonal therapy in advanced or recurrent endometrial cancer","volume":"12","author":"Kokka","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic oncology group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic oncology group study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0050","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic oncology group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic oncology group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0060","first-page":"1831","article-title":"CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors","volume":"79","author":"Bulun","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/978-0-387-78818-0_8","article-title":"Aromatase expression in women\u2019s cancers","volume":"630","author":"Bulun","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0070","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic oncology group study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0075","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2407-14-68","article-title":"Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)","volume":"14","author":"Lindemann","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2026.07.001_bb0080","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1136\/ijgc-00009577-200407000-00013","article-title":"The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Ma","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.001_bb0085","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ygyno.2013.09.023","article-title":"Neoadjuvant treatment of endometrial cancer using anastrozole: a randomised pilot study","volume":"131","author":"Thangavelu","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0090","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00689680","article-title":"Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells","volume":"31","author":"Watts","year":"1994","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0105","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1128\/MCB.21.3.794-810.2001","article-title":"Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function","volume":"21","author":"Foster","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0110","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1128\/MCB.17.7.4059","article-title":"Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution","volume":"17","author":"Planas-Silva","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0115","first-page":"1804","article-title":"Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation","volume":"9","author":"Watts","year":"1995","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0120","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/bcr2419","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1530\/ERC-10-0262","article-title":"Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer","volume":"18","author":"Thangavel","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.001_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0140","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/bjc.2015.369","article-title":"Prognostic importance of CDK4\/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy","volume":"113","author":"Ikeda","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.07.001_bb0145","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-24-1999","article-title":"A phase II study of Fulvestrant plus Abemaciclib in hormone receptor-positive advanced or recurrent endometrial cancer","volume":"31","author":"Green","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A phase II, two-stage study of letrozole and Abemaciclib in Estrogen receptor-positive recurrent endometrial cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0155","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/modpathol.2016.203","article-title":"Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies","volume":"30","author":"Kitson","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/antiox14030345","article-title":"The anti-cancer role of pterostilbene in endometrial cancer: a phase II prospective, randomized, window-of-opportunity clinical trial with megestrol acetate","volume":"14","author":"Senguttuvan","year":"2025","journal-title":"Antioxidants"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2026.07.001_bb0165","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0140-6736(15)60405-6","article-title":"A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer","volume":"385","author":"Sivalingam","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2026.07.001_bb0170","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-20-4618","article-title":"A surgical window trial evaluating medroxyprogesterone acetate with or without Entinostat in patients with endometrial cancer and validation of biomarkers of cellular response","volume":"27","author":"Duska","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.07.001_bb0180","series-title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","year":"2026"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:35:33Z","timestamp":1786149333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S0090825826020548"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}